Share this video  

ESMO WCGIC 2020 | Regorafenib + nivolumab in MMR proficient advanced CRC

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses results of a Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).